Published in Br J Cancer on August 01, 2000
NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet (2005) 5.01
N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene (2006) 2.03
Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol (2007) 1.96
Genetic susceptibility to occupational exposures. Occup Environ Med (2008) 0.87
Cytochrome P450 (CYP) 1A2, sulfotransferase (SULT) 1A1, and N-acetyltransferase (NAT) 2 polymorphisms and susceptibility to urothelial cancer. J Cancer Res Clin Oncol (2003) 0.83
Cytochrome P4501A2 phenotype and bladder cancer risk: The Shanghai bladder cancer study. Int J Cancer (2011) 0.83
Toxicological assessment of noxious inhalants. GMS Curr Top Otorhinolaryngol Head Neck Surg (2004) 0.75
Tumours of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. I. The role of aniline, benzidine, alpha-naphthylamine, and beta-naphthylamine. Br J Ind Med (1954) 6.59
A consumer's guide to subgroup analyses. Ann Intern Med (1992) 6.34
Spurious precision? Meta-analysis of observational studies. BMJ (1998) 5.45
Nomenclature for N-acetyltransferases. Pharmacogenetics (1995) 3.59
Minimum sample size estimation to detect gene-environment interaction in case-control designs. Am J Epidemiol (1994) 2.28
Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet (1982) 2.05
Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet (1995) 1.79
Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta (1988) 1.59
N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ Health Perspect (1979) 1.43
Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res (1998) 1.38
Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet (1995) 1.30
p53 expression and risk factors for cutaneous melanoma: a case-control study. Int J Cancer (1998) 1.22
Human acetyltransferase polymorphisms. Mutat Res (1997) 1.21
The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction. Cancer Res (1998) 1.20
Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics (1994) 1.15
Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res (1987) 1.12
Familial and environmental interactions in bladder cancer risk. Int J Cancer (1985) 1.11
Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol Biomarkers Prev (1997) 1.05
Polymorphic N-acetyltransferase (NAT2) genotyping of Emiratis. Pharmacogenetics (1997) 1.03
N-acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. Carcinogenesis (1993) 0.98
A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. J Med Genet (1997) 0.97
Polymorphic NATs and cancer predisposition. IARC Sci Publ (1999) 0.92
Review of studies of selected metabolic polymorphisms and cancer. IARC Sci Publ (1999) 0.92
N-Acetyltransferase phenotypes in the urinary bladder carcinogenesis of a low-risk population. Carcinogenesis (1985) 0.91
Association of N-acetyltransferase polymorphism and environmental factors with bladder carcinogenesis. Study in a north German population. Eur Urol (1985) 0.91
Epidemiological models of carcinogenesis: the example of bladder cancer. Cancer Epidemiol Biomarkers Prev (1993) 0.90
Hepatic acetylator phenotype in bladder cancer patients. Ann Clin Res (1985) 0.88
White blood cell DNA adducts, smoking, and NAT2 and GSTM1 genotypes in bladder cancer: a case-control study. Cancer Epidemiol Biomarkers Prev (1998) 0.88
Meta-analysis of phenotype and genotype of NAT2 deficiency in Chinese populations. Pharmacogenetics (1997) 0.87
Acetylation phenotypes and bladder cancer. J Occup Med (1990) 0.85
Interaction, subgroup analysis and sample size. IARC Sci Publ (1999) 0.84
The association of the slow acetylator phenotype with bladder cancer. J Med Genet (1983) 0.84
N-acetylation phenotype in bladder cancer. Hum Toxicol (1982) 0.84
CYP1A2 activity as a risk factor for bladder cancer. J Korean Med Sci (1994) 0.83
Genetic association with bladder cancer. Br Med J (1979) 0.82
Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer. Eur J Clin Pharmacol (1989) 0.82
The impact of misclassification in case-control studies of gene-environment interactions. IARC Sci Publ (1999) 0.82
N-acetyltransferase activity in the urine in Japanese subjects: comparison in healthy persons and bladder cancer patients. Jpn J Cancer Res (1995) 0.81
N-Acetyltransferase phenotype of patients with bladder cancer. Hum Toxicol (1986) 0.80
Acetylator phenotype in human bladder cancer. J Urol (1983) 0.80
N-acetyltransferase activity--a susceptibility factor in human bladder carcinogenesis. Indian J Cancer (1995) 0.80
Acetylation phenotypes in patients with bladder carcinoma. Ann Genet (1988) 0.80
Molecular genetics of bladder cancer: pathways of development and progression. Cancer Surv (1998) 0.80
The NAT2* slow acetylator genotype is associated with bladder cancer in Taiwanese, but not in the Black Foot Disease endemic area population. Pharmacogenetics (1998) 0.79
Familial transitional cell carcinoma among the population of Iceland. J Urol (1997) 0.77
[Determination of the N-acetyltransferase phenotype in urothelial cancer patients and healthy controls]. Hinyokika Kiyo (1986) 0.77
Analysis of p53, p16MTS, p21WAF1 and H-ras in archived bladder tumours from workers exposed to aromatic amines. Br J Cancer (1998) 0.76
Epidemiology of transitional cell carcinoma of the bladder: profile of an urban population in the south-west of England. Br J Urol (1998) 0.76
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 24.57
Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ (2000) 11.35
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet (2011) 10.62
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet (2011) 8.24
Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. BMJ (2004) 6.48
KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med (1996) 5.96
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Risk of Kaposi's sarcoma and sexual practices associated with faecal contact in homosexual or bisexual men with AIDS. Lancet (1992) 5.10
Catastrophic shoulder dystocia and emergency symphysiotomy. Am J Obstet Gynecol (1997) 3.98
Epidemiology of breast cancer. Lancet Oncol (2001) 3.58
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr (2010) 2.91
Variability in vitamin D assays impairs clinical assessment of vitamin D status. Intern Med J (2012) 2.67
Antibodies against human herpesvirus 8 in black South African patients with cancer. N Engl J Med (1999) 2.63
Cancer near potential sites of nuclear installations. Lancet (1989) 2.33
Coxsackie B virus serology and Type 1 diabetes mellitus: a systematic review of published case-control studies. Diabet Med (2004) 2.18
A framework for developing excellence as a clinical educator. Med Educ (2001) 2.14
Cancer near nuclear installations. Nature (1987) 1.98
Evaluation of a postal screening questionnaire to identify the physically disabled. Int Rehabil Med (1980) 1.94
Limitation of joint mobility (cheiroarthropathy) in adult noninsulin-dependent diabetic patients. Ann Rheum Dis (1984) 1.93
Efficacy of an internet-based behavioral weight loss program for overweight adolescent African-American girls. Eat Weight Disord (2005) 1.88
Genetic aspects of cerebral palsy. Dev Med Child Neurol (1992) 1.72
A Holy Grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Br J Pharmacol (2007) 1.71
Comparison of prevalence of schizophrenia among residents of hostels for homeless people in 1966 and 1992. BMJ (1994) 1.65
Review of the distribution of Kaposi's sarcoma-associated herpesvirus (KSHV) in Africa in relation to the incidence of Kaposi's sarcoma. Br J Cancer (2003) 1.60
Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol (1998) 1.59
The spectrum of HIV-1 related cancers in South Africa. Int J Cancer (2000) 1.58
Use of HRT and the subsequent risk of cancer. J Epidemiol Biostat (1999) 1.57
Hormone replacement therapy and high incidence of breast cancer between mammographic screens. Lancet (1997) 1.51
Human labour is associated with nuclear factor-kappaB activity which mediates cyclo-oxygenase-2 expression and is involved with the 'functional progesterone withdrawal'. Mol Hum Reprod (2001) 1.51
Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res (1998) 1.48
Radiation risks. Appropriate decisions come from valid data, not inaccurate perceptions of risk. BMJ (1999) 1.48
Management of an acute painful sickle cell episode in hospital: summary of NICE guidance. BMJ (2012) 1.47
Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol (2007) 1.46
High-risk prescribing and incidence of frailty among older community-dwelling men. Clin Pharmacol Ther (2012) 1.43
Adverse reactions to carbamazepine managed by desensitisation. Lancet (1985) 1.42
Sodium salicylate inhibits cyclo-oxygenase-2 activity independently of transcription factor (nuclear factor kappaB) activation: role of arachidonic acid. Mol Pharmacol (1997) 1.38
The geographical distribution of Kaposi's sarcoma and of lymphomas in Africa before the AIDS epidemic. Br J Cancer (1998) 1.36
Poverty and eosinophilia are risk factors for endomyocardial fibrosis (EMF) in Uganda. Trop Med Int Health (1999) 1.34
The cumulative risk of lung cancer among current, ex- and never-smokers in European men. Br J Cancer (2004) 1.34
TGFbeta1 allele association with asthma severity. Hum Genet (2001) 1.33
Individuals from North America, Australasia, and Africa are infected with four different genotypes of human herpesvirus 8. Virology (1999) 1.32
Cancer and HIV infection in Rwanda. Lancet (1995) 1.31
Relationship of height, weight and body mass index to the risk of hip and knee replacements in middle-aged women. Rheumatology (Oxford) (2007) 1.31
Tumor necrosis factor-alpha is a potent ACTH secretagogue: comparison to interleukin-1 beta. Endocrinology (1989) 1.31
Estimation of the impact of genital warts on health-related quality of life. Sex Transm Infect (2008) 1.31
Risk factors for oesophageal, lung, oral and laryngeal cancers in black South Africans. Br J Cancer (2002) 1.30
A novel leukocyte adhesion deficiency caused by expressed but nonfunctional beta2 integrins Mac-1 and LFA-1. J Clin Invest (1999) 1.29
A dictionary-based approach for gene annotation. J Comput Biol (1999) 1.29
Overview of the epidemiology of immunodeficiency-associated cancers. J Natl Cancer Inst Monogr (1998) 1.28
Energy balance and cancer: the role of sex hormones. Proc Nutr Soc (2001) 1.27
Kaposi's sarcoma in South Africa. J Natl Cancer Inst Monogr (2001) 1.25
Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol (1996) 1.23
Serologic evidence for mother-to-child transmission of Kaposi sarcoma-associated herpesvirus infection. JAMA (1998) 1.22
Risk factors for Kaposi's sarcoma in HIV-positive subjects in Uganda. AIDS (1997) 1.21
A multicenter case-control study of diet and lung cancer among non-smokers. Cancer Causes Control (2000) 1.20
Spectrum and presentation of pediatric malignancies in the HIV era: experience from Blantyre, Malawi, 1998-2003. Pediatr Blood Cancer (2007) 1.20
Knowledge of renal histology alters patient management in over 40% of cases. Nephrol Dial Transplant (1994) 1.20
Corneo-conjunctival carcinoma in Uganda. Eye (Lond) (2006) 1.19
A randomized control trial of the effect of negotiated telephone support on glycaemic control in young people with Type 1 diabetes. Diabet Med (2002) 1.18
The effect of oral sodium phosphate on the formation of renal calculi and on idiopathic hypercalcuria. Lancet (1966) 1.18
Beyond the dogma: novel beta2-adrenoceptor signalling in the airways. Eur Respir J (2006) 1.18
Unusual presentation of phaeochromocytoma. Management of anaesthesia and cardiovascular monitoring. Anaesthesia (1976) 1.17
Sclerosing cholangitis associated with multifocal fibrosis: a case report. Gut (1992) 1.17
Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet (1972) 1.17
The LIM-only factor LMO4 regulates expression of the BMP7 gene through an HDAC2-dependent mechanism, and controls cell proliferation and apoptosis of mammary epithelial cells. Oncogene (2007) 1.14
Prognostic value of coronary revascularisation-related myocardial injury: a cardiac magnetic resonance imaging study. Heart (2009) 1.14
Increasing probability of mother-to-child transmission of HHV-8 with increasing maternal antibody titer for HHV-8. N Engl J Med (1999) 1.12
NF-kappaB and AP-1 are required for cyclo-oxygenase 2 gene expression in amnion epithelial cell line (WISH). Mol Hum Reprod (2000) 1.09
Time course and nerve growth factor dependence of inflammation-induced alterations in electrophysiological membrane properties in nociceptive primary afferent neurons. J Neurosci (2001) 1.09
Equilibrium and kinetic studies of the interactions of salmeterol with membrane bilayers. Mol Pharmacol (1992) 1.08
A question sheet to encourage written consultation questions. Qual Health Care (2000) 1.08
Expression of cyclooxygenase types 1 and 2 in human fetal membranes at term. Am J Obstet Gynecol (1995) 1.08
Extradural analgesia in labour when the breech presents. Br J Obstet Gynaecol (1976) 1.07
Self-funding and community care admissions to nursing homes in Aberdeen. Health Bull (Edinb) (1996) 1.06
Plasma and salivary pharmacokinetics of caffeine in man. Eur J Clin Pharmacol (1981) 1.04
Expression of RANTES mRNA and protein in airways of patients with mild asthma. Am J Respir Crit Care Med (1996) 1.04
Women doctors' use of hormone replacement therapy. High prevalence of use is not confined to doctors. BMJ (1996) 1.03
Intention to treat febrile convulsions with rectal diazepam, valproate or phenobarbitone. Dev Med Child Neurol (1989) 1.02
Physical fitness qualities of professional rugby league football players: determination of positional differences. J Strength Cond Res (2001) 1.02
Two distinct phospholipases C of Listeria monocytogenes induce ceramide generation, nuclear factor-kappa B activation, and E-selectin expression in human endothelial cells. J Immunol (1998) 0.98
Phagocytosis-promoting activity of avian plasma and fibroblastic cell surface fibronectins. Mol Cell Biochem (1981) 0.97
Gonadotrophins and ovarian cancer risk. J Natl Cancer Inst (1985) 0.97
Treatment of Kaposi's sarcoma in HIV-1 infected individuals with emphasis on resource poor settings. Cochrane Database Syst Rev (2003) 0.97
Antibodies against six human herpesviruses in relation to seven cancers in black South Africans: a case control study. Infect Agent Cancer (2006) 0.96
Expression of COX-2 by normal and reactive astrocytes in the adult rat central nervous system. Mol Cell Neurosci (1999) 0.96
Molecular regulation of granulocyte macrophage colony-stimulating factor in human lung epithelial cells by interleukin (IL)-1beta, IL-4, and IL-13 involves both transcriptional and post-transcriptional mechanisms. Am J Respir Cell Mol Biol (2000) 0.96
Alpha-melanocyte-stimulating hormone exhibits target cell selectivity in its capacity to affect interleukin 1-inducible responses in vivo and in vitro. J Immunol (1987) 0.95
Demonstration of fluid channels in human dura and their relationship to age and intradural bleeding. Childs Nerv Syst (2009) 0.95
Definition and estimation of lifetime detriment from radiation exposures: principles and methods. Health Phys (1992) 0.94
Attitudes and background factors related to alcohol use among college students. Psychol Rep (1980) 0.94
Differential regulation of cyclo-oxygenase-1 and cyclo-oxygenase-2 gene expression by lipopolysaccharide treatment in vivo in the rat. Clin Sci (Lond) (1996) 0.93
Adenosine 3',5'-cyclic monophosphate (cAMP)-dependent inhibition of IL-5 from human T lymphocytes is not mediated by the cAMP-dependent protein kinase A. J Immunol (2001) 0.93
Induction of cyclooxygenase-2 in human saphenous vein and internal mammary artery. Arterioscler Thromb Vasc Biol (1997) 0.93